LLY

753.41

3.25% 23.68

시장 영업 전: 752.89 -0.52 -0.07%

일라이 릴리 (LLY)

개요 뉴스 가격 이력 옵션 체인 Financials LLY 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$729.73

열려 있는:

$735.785

하루 거래량:

4.92M

Relative Volume:

1.53

시가총액:

$693.54B

수익:

$40.86B

순이익/손실:

$8.37B

주가수익비율:

139.02

EPS:

5.4193

순현금흐름:

$-2.28B

1주 성능:

-7.19%

1개월 성능:

-17.93%

6개월 성능:

-3.80%

1년 성능:

+26.07%

1일 변동 폭

$735.46

$757.37

1주일 범위

$711.40

$809.19

52주 변동 폭

$561.65

$972.53

일라이 릴리 Stock (LLY) Company Profile

명칭

Lilly Eli Co

부문

Healthcare (1193)

산업

Drug Manufacturers - General (18)

전화

(317) 276-2000

주소

LILLY CORPORATE CTR, INDIANAPOLIS, IN

직원

43,000

트위터

@LillyPad

다음 수익 날짜

2024-10-30

최신 SEC 제출 서류

LLY's Discussions on Twitter

LLY을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
LLY	753.41	693.54B	40.86B	8.37B	-2.28B	5.4193
NVO	105.27	465.74B	39.36B	13.79B	9.83B	2.4077
JNJ	153.11	353.35B	87.70B	14.68B	19.03B	13.47
ABBV	167.76	294.70B	55.53B	5.12B	15.62B	3.65
MRK	97.44	248.54B	63.17B	12.15B	14.84B	1.80

일라이 릴리 Stock (LLY) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-11-15	개시	Wolfe Research	Outperform
2024-10-17	개시	Bernstein	Outperform
2024-09-13	재개	Citigroup	Buy
2024-08-12	업그레이드	Deutsche Bank	Hold → Buy
2024-02-21	다운그레이드	DZ Bank	Buy → Hold
2024-02-16	재확인	Morgan Stanley	Overweight
2023-12-21	다운그레이드	Daiwa Securities	Buy → Outperform
2023-11-09	개시	Deutsche Bank	Hold
2023-10-20	재개	UBS	Buy
2023-08-09	업그레이드	Jefferies	Hold → Buy
2023-07-26	재확인	Citigroup	Buy
2023-07-14	개시	HSBC Securities	Buy
2023-05-24	재확인	BofA Securities	Buy
2023-05-24	재확인	UBS	Buy
2023-03-13	업그레이드	Wells Fargo	Equal Weight → Overweight
2023-03-06	개시	Jefferies	Hold
2023-02-15	다운그레이드	Societe Generale	Hold → Sell
2022-11-18	개시	Credit Suisse	Outperform
2022-09-22	업그레이드	UBS	Neutral → Buy
2022-05-23	개시	SVB Leerink	Outperform
2022-04-06	재개	Morgan Stanley	Overweight
2022-03-10	개시	Daiwa Securities	Outperform
2022-01-21	업그레이드	DZ Bank	Hold → Buy
2022-01-03	재확인	Bernstein	Mkt Perform
2021-12-17	개시	Goldman	Neutral
2021-12-16	재확인	BMO Capital Markets	Outperform
2021-12-16	재확인	BofA Securities	Buy
2021-12-09	재개	Wells Fargo	Equal Weight
2021-11-19	개시	BMO Capital Markets	Outperform
2021-10-11	업그레이드	Berenberg	Hold → Buy
2021-09-29	업그레이드	Citigroup	Neutral → Buy
2021-08-05	업그레이드	DZ Bank	Hold → Buy
2021-07-27	재개	Truist	Buy
2021-06-24	재확인	Cantor Fitzgerald	Overweight
2021-01-19	업그레이드	Mizuho	Neutral → Buy
2020-12-10	업그레이드	Wolfe Research	Peer Perform → Outperform
2020-11-10	재개	Bernstein	Mkt Perform
2020-09-29	개시	Berenberg	Hold
2020-09-03	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2020-06-16	업그레이드	Guggenheim	Neutral → Buy
2020-04-21	다운그레이드	UBS	Buy → Neutral
2020-04-09	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2020-02-06	개시	Mizuho	Neutral
2019-12-18	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2019-10-17	재개	BofA/Merrill	Buy
2019-05-28	개시	Goldman	Buy
2019-04-24	업그레이드	Edward Jones	Hold → Buy
2019-04-11	다운그레이드	Guggenheim	Buy → Neutral
2019-03-12	개시	JP Morgan	Overweight
2019-01-23	개시	UBS	Buy
2018-11-26	다운그레이드	Citigroup	Buy → Neutral
2018-10-31	업그레이드	Credit Suisse	Underperform → Neutral
2018-10-09	개시	Guggenheim	Buy
2018-10-01	재확인	SunTrust	Buy
2018-09-26	재개	JP Morgan	Overweight

모두보기

일라이 릴리 주식(LLY)의 최신 뉴스

05:15 AM

Eli Lilly, Verge announce milestones in ALS collaboration - Yahoo Finance

05:15 AM

Nov 20, 2024

Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’ - Insider Monkey

Nov 20, 2024

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug - Reuters

Nov 20, 2024

Oceanside Unified takes on Eli Lilly and CVS Caremark in insulin pricing lawsuit - CBS News 8

Nov 20, 2024

Eli Lilly and China-based biotech Laekna team on obesity drug - TipRanks

Nov 20, 2024

Eli Lilly in pact for novel weight loss therapy (LLY:NYSE) - Seeking Alpha

Nov 20, 2024

UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Australia

Nov 20, 2024

UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday - Investing.com

Nov 20, 2024

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity - BioSpace

Nov 20, 2024

Lilly to develop ALS therapeutics against targets identified under Verge collaboration - BioWorld Online

Nov 20, 2024

Is Novo Nordisk Stock a Buy Right Now? - The Motley Fool

Nov 20, 2024

Is It Time to Sell Eli Lilly and Pfizer Stocks? - The Motley Fool

Nov 20, 2024

The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley - Yahoo Finance

Nov 20, 2024

Eli Lilly: Procter & Gamble CEO joins board - Marketscreener.com

Nov 20, 2024

Nov 19, 2024

Eli Lilly and Company (LLY) Announces Board Changes: Jon Moeller Joins, Karen Walker Resigns - GuruFocus.com

Nov 19, 2024

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial - CNBC

Nov 19, 2024

Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip? - Benzinga

Nov 19, 2024

Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86% - Yahoo Finance

Nov 19, 2024

Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss - TipRanks

Nov 19, 2024

Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund - Yahoo Finance

Nov 19, 2024

Lilly’s Lp(a) targeting candidate muvalaplin meets primary endpoint in Phase 2 trial - World Pharmaceutical Frontiers

Nov 19, 2024

Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease - OutSourcing-Pharma.com

Nov 19, 2024

Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters.com

Nov 19, 2024

Nov 18, 2024

Cramer's Lightning Round: Eli Lilly is a buy - NECN

Nov 18, 2024

Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha

Nov 18, 2024

Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Reuters

Nov 18, 2024

Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial - TipRanks

Nov 18, 2024

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose - Investors | Eli Lilly and Company

Nov 18, 2024

Eli Lilly follows J&J in suing Biden administration over 340B rebates - Healthcare Dive

Nov 18, 2024

Tesla, Eli Lilly lead market cap stock movers on Monday By Investing.com - Investing.com South Africa

Nov 18, 2024

Revisto, Inc announced that it has received $4 million in funding from LiveOak Ventures, Eli Lilly and Company, TAU VENTURES, Arkin Digital Health - Marketscreener.com

Nov 18, 2024

Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Benzinga

Nov 18, 2024

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Nov 18, 2024

Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints - Marketscreener.com

Nov 18, 2024

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.

Nov 18, 2024

Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF - Clinical Trials Arena

Nov 18, 2024

Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients (NYSE:LLY) - Seeking Alpha

Nov 18, 2024

Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Colorado Springs Gazette

Nov 18, 2024

Eli Lilly: positive results for tirzepatide - Marketscreener.com

Nov 18, 2024

Nov 17, 2024

If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now - The Motley Fool

Nov 17, 2024

Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? - Yahoo! Voices

Nov 17, 2024

Nov 16, 2024

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity - Investors | Eli Lilly and Company

Nov 16, 2024

Nov 15, 2024

Eli Lilly Says HHS Ignores Drug Discount Double-Dipping - Law360

Nov 15, 2024

Lilly Sues U.S. to Change Hospital Drug Discount Payments - The Wall Street Journal

Nov 15, 2024

Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024